Very Low LDL Levels Best in Secondary Prevention: Ez‑PAVE

New randomized data from the Ez‑PAVE trial show that targeting low‑density lipoprotein cholesterol (LDL‑C) below 55 mg/dL meaningfully reduces major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) compared with the more conventional threshold of less than 70 mg/dL. The findings, presented at the American College of Cardiology 2026 Scientific Session and published in the New England Journal of Medicine, provide the first direct evidence that the stricter LDL goal promoted in the updated American dyslipidemia guidelines is superior for secondary prevention.

Key findings from Ez‑PAVE

In Ez‑PAVE, 3,048 patients with established ASCVD were randomized to an LDL‑C target of less than 55 mg/dL or less than 70 mg/dL across 17 South Korean sites. Over a median follow‑up of 3 years, the intensive‑target group achieved a median LDL of 56 mg/dL versus 66 mg/dL in the less‑intensive arm. The primary composite endpoint—cardiovascular death, nonfatal MI, nonfatal stroke, any revascularization, or hospitalization for unstable angina—occurred in 6.6% of the < 55 mg/dL group versus 9.7% of the < 70 mg/dL group, corresponding to a 33% relative‑risk reduction (HR 0.67).

Both nonfatal MI and any revascularization were significantly lower in the lower‑target group, with consistent benefit across age, diabetes status, and baseline risk profile. Although the trial was underpowered for sex‑specific analyses, the editorial in the NEJM notes that the overall pattern aligns with prior lipid‑lowering trials showing similar benefit in men and women. Safety outcomes, including new‑onset diabetes, statin‑associated muscle symptoms, cancer, and liver or kidney‑related events, were similar between groups, with a small but statistically significant reduction in creatinine elevation in the intensive‑target arm.

How this aligns with the new US guidelines

The 2026 ACC/AHA dyslipidemia guidelines recommend targeting LDL‑C below 70 mg/dL for high‑risk patients and below 55 mg/dL for very high‑risk individuals, typically using statin‑based therapy plus ezetimibe or a PCSK9 inhibitor. Ez‑PAVE strongly supports the 55 mg/dL target in secondary prevention, demonstrating that intensifying lipid‑lowering with high‑intensity statins and ezetimibe, and escalating to PCSK9 inhibitors when necessary, improves outcomes without a clear safety trade‑off.

Experts such as Christopher P. Cannon, MD stress that the event‑reduction curves separate early and remain stable, reinforcing the “lower is better” paradigm and suggesting that 55 mg/dL should become a default goal for most ASCVD patients. Christie Ballantyne, MD has argued that the high‑risk/very‑high‑risk distinction may be unnecessarily complex and that a single, lower LDL‑C target for all secondary‑prevention patients could ease guideline implementation.

Clinical implications for the practicing cardiologist

For a cardiologist managing ASCVD, Ez‑PAVE shifts the practical standard: aiming for LDL‑C below 55 mg/dL, using statin plus ezetimibe as a first‑line intensification and reserving PCSK9 inhibitors for patients who cannot reach goal or cannot tolerate high‑dose statins, appears both safe and effective. The trial also underscores the importance of close lab monitoring, dose titration, and adherence support, since many patients needed multiple adjustments over 3 years to sustain their target LDL.

At the same time, the authors and editorialists caution that Ez‑PAVE was conducted in a South Korean (predominantly Asian) ASCVD population, so direct extrapolation to other ethnic groups—especially in primary‑prevention settings—requires further study. The trial does not define whether all primary‑prevention patients must be targeted below 70 mg/dL, but it does solidify that in secondary prevention, “lower LDL now” is where the strongest outcome signal lies.

---

Checklists for the practicing cardiologist

1. Patient selection: who to target below 55 mg/dL

• Confirm established atherosclerotic cardiovascular disease (ASCVD) (prior MI, ischemic stroke, PAD, or coronary revascularization).

• Ensure patient has LDL‑C ≥ 55 mg/dL at baseline on guideline‑directed lipid‑lowering therapy.

• Exclude patients with contraindications to statins, ezetimibe, or PCSK9 inhibitors or those with life‑limiting non‑cardiovascular disease and very short life expectancy.

2. Lipid‑lowering strategy in ASCVD

• Start or intensify high‑intensity statin (e.g., atorvastatin 40–80 mg or rosuvastatin 20–40 mg) unless contraindicated.

• Add ezetimibe 10 mg daily if LDL‑C remains above 55 mg/dL despite maximal tolerated statin dose.

• Consider PCSK9 inhibitor (alirocumab or evolocumab) if LDL‑C remains ≥ 55 mg/dL after statin plus ezetimibe, or if the patient has multiple prior events or very high‑risk features.

3. Monitoring and titration

• Measure fasting LDL‑C 4–8 weeks after any regimen change and at least annually once at target.

• Titrate statin dose or ezetimibe to achieve LDL‑C < 55 mg/dL in ASCVD patients, with individualized targets if CKD or other comorbidities modify risk.

• Document reasons for changes in therapy (e.g., statin‑associated muscle symptoms, liver‑function‑test elevation) and whether the LDL‑C target was achieved before de‑intensifying.

4. Safety and comorbidity optimization

• Monitor for new‑onset diabetes and worsening glycemia in patients with prediabetes or diabetes, but do not withhold statin if LDL‑C benefit outweighs risk.

• Assess for statin‑associated muscle symptoms; consider short‑term dose reduction or intermittent dosing rather than full discontinuation if LDL‑C remains above target.

• Continue standard CV‑risk‑factor optimization (BP control, smoking cessation, weight management, diabetes control) regardless of LDL‑C target.

5. Counseling and documentation

• Educate patients that “lower LDL now” is associated with lower cardiovascular risk, using simple language (e.g., 30% relative risk reduction when LDL‑C is lowered to < 55 mg/dL).

• Document the LDL‑C target set in the EMR (e.g., “LDL‑C < 55 mg/dL in secondary prevention”) and update it after each lipid panel.

• Flag patients who remain above 55 mg/dL despite maximal tolerated oral therapy for discussion of PCSK9 inhibitor use, including cost‑effectiveness and insurance coverage.

6. Special considerations

• For women with ASCVD, aim for the same LDL‑C target as men unless data from future sex‑specific analyses suggest otherwise.

• For non‑South Asian or primary‑prevention populations, adopt the 55 mg/dL target cautiously, weighing trial generalizability and individual patient risk.

• In high‑bleeding‑risk or frail patients, balance LDL‑C goals against overall life expectancy, bleeding risk, and treatment burden.